Logo image of LEGN

LEGEND BIOTECH CORP-ADR (LEGN) Stock Fundamental Analysis

USA - NASDAQ:LEGN - US52490G1022 - ADR

31.86 USD
+0.19 (+0.6%)
Last: 10/24/2025, 8:00:02 PM
32 USD
+0.14 (+0.44%)
After Hours: 10/24/2025, 8:00:02 PM
Fundamental Rating

4

LEGN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. The financial health of LEGN is average, but there are quite some concerns on its profitability. LEGN shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year LEGN has reported negative net income.
In the past year LEGN has reported a negative cash flow from operations.
In the past 5 years LEGN always reported negative net income.
LEGN had a negative operating cash flow in each of the past 5 years.
LEGN Yearly Net Income VS EBIT VS OCF VS FCFLEGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

With a decent Return On Assets value of -19.25%, LEGN is doing good in the industry, outperforming 77.15% of the companies in the same industry.
Looking at the Return On Equity, with a value of -31.42%, LEGN is in the better half of the industry, outperforming 76.22% of the companies in the same industry.
Industry RankSector Rank
ROA -19.25%
ROE -31.42%
ROIC N/A
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
LEGN Yearly ROA, ROE, ROICLEGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

The Gross Margin of LEGN (62.51%) is better than 79.40% of its industry peers.
LEGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LEGN Yearly Profit, Operating, Gross MarginsLEGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

4

2. Health

2.1 Basic Checks

LEGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LEGN has been increased compared to 1 year ago.
LEGN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for LEGN is higher compared to a year ago.
LEGN Yearly Shares OutstandingLEGN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
LEGN Yearly Total Debt VS Total AssetsLEGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

LEGN has an Altman-Z score of 6.93. This indicates that LEGN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of LEGN (6.93) is better than 77.53% of its industry peers.
A Debt/Equity ratio of 0.37 indicates that LEGN is not too dependend on debt financing.
LEGN has a worse Debt to Equity ratio (0.37) than 70.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Altman-Z 6.93
ROIC/WACCN/A
WACC9.09%
LEGN Yearly LT Debt VS Equity VS FCFLEGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 4.71 indicates that LEGN has no problem at all paying its short term obligations.
LEGN has a Current ratio (4.71) which is comparable to the rest of the industry.
A Quick Ratio of 4.57 indicates that LEGN has no problem at all paying its short term obligations.
LEGN has a Quick ratio of 4.57. This is comparable to the rest of the industry: LEGN outperforms 52.06% of its industry peers.
Industry RankSector Rank
Current Ratio 4.71
Quick Ratio 4.57
LEGN Yearly Current Assets VS Current LiabilitesLEGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

7

3. Growth

3.1 Past

The earnings per share for LEGN have decreased strongly by -12.18% in the last year.
Looking at the last year, LEGN shows a very strong growth in Revenue. The Revenue has grown by 74.75%.
Measured over the past years, LEGN shows a very strong growth in Revenue. The Revenue has been growing by 59.90% on average per year.
EPS 1Y (TTM)-12.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-580%
Revenue 1Y (TTM)74.75%
Revenue growth 3Y108.91%
Revenue growth 5Y59.9%
Sales Q2Q%36.74%

3.2 Future

LEGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.58% yearly.
Based on estimates for the next years, LEGN will show a very strong growth in Revenue. The Revenue will grow by 36.23% on average per year.
EPS Next Y-39.79%
EPS Next 2Y62.28%
EPS Next 3Y52.8%
EPS Next 5Y37.58%
Revenue Next Year69.13%
Revenue Next 2Y59.43%
Revenue Next 3Y51.21%
Revenue Next 5Y36.23%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
LEGN Yearly Revenue VS EstimatesLEGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
LEGN Yearly EPS VS EstimatesLEGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LEGN. In the last year negative earnings were reported.
LEGN is valuated quite expensively with a Price/Forward Earnings ratio of 52.95.
Compared to the rest of the industry, the Price/Forward Earnings ratio of LEGN indicates a rather cheap valuation: LEGN is cheaper than 88.95% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of LEGN to the average of the S&P500 Index (22.92), we can say LEGN is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 52.95
LEGN Price Earnings VS Forward Price EarningsLEGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LEGN Per share dataLEGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

LEGN's earnings are expected to grow with 52.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y62.28%
EPS Next 3Y52.8%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LEGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEGEND BIOTECH CORP-ADR

NASDAQ:LEGN (10/24/2025, 8:00:02 PM)

After market: 32 +0.14 (+0.44%)

31.86

+0.19 (+0.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners47.54%
Inst Owner Change-0.31%
Ins Owners0.08%
Ins Owner ChangeN/A
Market Cap5.84B
Revenue(TTM)796.84M
Net Income(TTM)-325333000
Analysts83.2
Price Target76.5 (140.11%)
Short Float %10.7%
Short Ratio8.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-239.55%
Min EPS beat(2)-351.12%
Max EPS beat(2)-127.98%
EPS beat(4)1
Avg EPS beat(4)-96.8%
Min EPS beat(4)-351.12%
Max EPS beat(4)143.99%
EPS beat(8)5
Avg EPS beat(8)-30.97%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.98%
Min Revenue beat(2)-1.23%
Max Revenue beat(2)9.2%
Revenue beat(4)3
Avg Revenue beat(4)4.83%
Min Revenue beat(4)-1.23%
Max Revenue beat(4)9.2%
Revenue beat(8)4
Avg Revenue beat(8)1.39%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.04%
PT rev (3m)-1.62%
EPS NQ rev (1m)18.61%
EPS NQ rev (3m)-50.94%
EPS NY rev (1m)-51.5%
EPS NY rev (3m)-131.94%
Revenue NQ rev (1m)-0.54%
Revenue NQ rev (3m)1.17%
Revenue NY rev (1m)0.56%
Revenue NY rev (3m)2.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 52.95
P/S 7.33
P/FCF N/A
P/OCF N/A
P/B 5.64
P/tB 5.66
EV/EBITDA N/A
EPS(TTM)-1.75
EYN/A
EPS(NY)0.6
Fwd EY1.89%
FCF(TTM)-1.58
FCFYN/A
OCF(TTM)-1.5
OCFYN/A
SpS4.34
BVpS5.64
TBVpS5.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -19.25%
ROE -31.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.51%
FCFM N/A
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.37
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 67.19%
Cap/Sales 1.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.71
Quick Ratio 4.57
Altman-Z 6.93
F-Score3
WACC9.09%
ROIC/WACCN/A
Cap/Depr(3y)97.56%
Cap/Depr(5y)226.91%
Cap/Sales(3y)9.76%
Cap/Sales(5y)32.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-580%
EPS Next Y-39.79%
EPS Next 2Y62.28%
EPS Next 3Y52.8%
EPS Next 5Y37.58%
Revenue 1Y (TTM)74.75%
Revenue growth 3Y108.91%
Revenue growth 5Y59.9%
Sales Q2Q%36.74%
Revenue Next Year69.13%
Revenue Next 2Y59.43%
Revenue Next 3Y51.21%
Revenue Next 5Y36.23%
EBIT growth 1Y41.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year65.66%
EBIT Next 3Y61.72%
EBIT Next 5Y36.12%
FCF growth 1Y61.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.38%
OCF growth 3YN/A
OCF growth 5YN/A

LEGEND BIOTECH CORP-ADR / LEGN FAQ

What is the ChartMill fundamental rating of LEGEND BIOTECH CORP-ADR (LEGN) stock?

ChartMill assigns a fundamental rating of 4 / 10 to LEGN.


What is the valuation status for LEGN stock?

ChartMill assigns a valuation rating of 2 / 10 to LEGEND BIOTECH CORP-ADR (LEGN). This can be considered as Overvalued.


Can you provide the profitability details for LEGEND BIOTECH CORP-ADR?

LEGEND BIOTECH CORP-ADR (LEGN) has a profitability rating of 2 / 10.


What is the expected EPS growth for LEGEND BIOTECH CORP-ADR (LEGN) stock?

The Earnings per Share (EPS) of LEGEND BIOTECH CORP-ADR (LEGN) is expected to decline by -39.79% in the next year.